Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

VOLUNTARY ANNOUNCEMENT

ANNOUNCEMENT IN RELATION TO RECEIVING THE NOTICE OF APPROVAL FOR CLINICAL TRIAL

This announcement is made by the board of directors (the "**Board**") of Tong Ren Tang Technologies Co. Ltd. (the "**Company**") on a voluntary basis.

The Board is pleased to announce that the pharmaceutical factory of the Company recently received the Notice of Approval for Clinical Trial of Medicine (《藥物臨床試驗批准通知書》) issued by the National Medical Products Administration. Details are as follows:

I. Basic information of the medicine

Name of the medicine: Qishen Granules (芪參顆粒)

Applicant: Tong Ren Tang Technologies Co. Ltd. Pharmaceutical Factory

Category of registration: Registration category 1.1 of traditional Chinese medicines

Indications: Benefiting qi and warming yang, and promoting blood circulation and detoxication. Curing for the syndrome of chronic heart failure due to qi deficiency and blood stasis.

Acceptance number: CXZL2300074

Notice number: 2024LP00491

Review conclusion: According to the Drug Administration Law of the People's Republic of China (《中華人民共和國藥品管理法》) / Vaccine Administration Law of the People's Republic of China (《中華人民共和國疫苗管理法》) and relevant regulations, Qishen Granules (芪參顆粒) was approved to use in clinical trial for chronic heart failure with reduced ejection fraction.

II. Research and development of the medicine and related information

The Qishen Granules (芪参颗粒) applied for clinical trial by the pharmaceutical factory of the Company is a traditional Chinese medicine compound preparation, which is applied according to the registration category 1.1 of traditional Chinese medicines and is intended to be used for chronic heart failure syndrome of qi deficiency and blood stasis. As at the date of this announcement, the Company has invested approximately RMB7.8 million (unaudited) in the research and development of Qishen Granules (芪参颗粒).

III. Risk warning

In accordance with the requirements of the relevant laws and regulations on registration of medicine in the PRC, a clinical trial of medicine shall be performed upon receiving the approval for the clinical trial and the medicine shall be produced and marketed only upon being assessed and scrutinized by the National Medical Products Administration. Given its special nature and long cycle from clinical trials to production upon approval which involves many stages, the research and development of medicine are susceptible to many unpredictable factors. There are uncertainties in the progress and results of clinical trials and the future competitive landscape of the pharmaceutical market. Investors are advised to consider the risks involved and be cautious in making investment decisions.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Di Shu Bing
Chairman of the Board

Beijing, the PRC
5 March 2024

As at the date of this announcement, the Board comprises Mr. Di Shu Bing, Mr. Chen Jia Fu and Ms. Feng Zhi Mei as executive Directors, Mr. Jin Tao, Ms. Wang Chun Rui and Ms. Feng Li as non-executive Directors, Mr. Ting Leung Huel, Stephen, Ms. Chan Ching Har, Eliza and Mr. Zhan Yuan Jing as independent non-executive Directors.